GeneSolve is the world’s first dedicated body chemistry company, with offices in the San Francisco Bay Area and Dallas, Texas. GeneSolve doctors utilize extensive laboratory tests and genetic analysis to provide personalized preventative health care programs to individual patients, as well as to groups through corporate wellness programs.
Bridgeway Care Ctr is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At DCHS, our mission is simple: to improve health every day. We are seeking providers to join our group who will share in our mission and help to cultivate our vision…to be the healthcare provider of choice for the communities we serve. Be an integral partner with one of the country`s top-ranked, most respected healthcare systems. As a system, DCHS is dedicated to purchasing the most advanced technology, operating state-of-the-art facilities and introducing new and innovative models of care. Vision, passion, perseverance, knowledge, skill, dedication, warmth, caring, technology, and people, have come together like a finely woven tapestry to create a healthcare experience for our patients that we call the Dickinson Difference.
Fresenius Kabi is a global health care company that specializes in lifesaving medicines and medical technologies for infusion, transfusion and clinical nutrition. Our expansive portfolio of products and global network of science and manufacturing centers provide essential support for the care of critical and chronically ill patients. We are part of Fresenius SE, a health care group with more than 100 years of experience in pharmaceuticals, medical devices and life sciences. Our employees – more than 35,000 worldwide – develop and deliver injectable pharmaceuticals and infusion systems; blood collection, transfusion and cell technologies; and essential nutrients for parenteral nutrition. We have special expertise in medicines for oncology, infection, anesthesia, analgesia and critical care. Our products are used in all sites of care – from hospitals and clinics to blood and plasma centers, and increasingly in patients’ homes. In biosimilars, we are developing products with a focus on oncology and autoimmune diseases.
Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of prescription medicines for pets in the United States and Europe. It develops AT-001, a prostaglandin E receptor 4 antagonist to treat the pain and inflammation associated with osteoarthritis in dogs, as well as for the management of pain in cats; AT-002, a potent and selective ghrelin agonist for the stimulation of appetite in cats and dogs; and AT-003, a bupivacaine liposome injectable suspension to manage post-operative pain in cats and dogs following surgery. The company was founded in 2010 and is headquartered in Kansas City, Kansas.